Kemoplat Dosage/Direction for Use

Metastatic Testicular Cancer: The usual dose for the treatment of testicular cancer in combination with other approved chemotherapeutic agents is 20 mg/m² I.V. daily for 5 days per cycle.
Metastatic Ovarian Cancer: The usual cisplatin dose for the treatment of metastatic ovarian cancer in combination with cyclophosphamide is 75-100 mg/m² I.V. per cycle once every 4 weeks. As a single agent cisplatin should be administered as 100 mg/m²/cycle I.V. every 4 weeks.
Advanced Bladder Cancer: Cisplatin should be administered as a single agent at a dose of 50-70 mg/m² I.V. per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. For heavily pretreated patients an initial dose of 50 mg/m² per cycle repeated every four weeks is recommended.
Pre Treatment Hydration: Patients should be adequately hydrated before and for 24 hrs. after KEMOPLAT 1 mg/ml administration in order to induce diuresis and minimize nephrotoxicity. Hydration may be achieved either by I.V. infusion of 2 liters of 0.9% sodium chloride or dextrose saline (Dextrose 5% in one fifth normal saline (0.18% Sodium chloride injection)) over a 6-12 hr. period. During the last 30 minutes of the pre treatment hydration or after the hydration, 375 ml of 20% mannitol injection may be administered via a side arm drip.
Preparation of KEMOPLAT 1 mg/ml infusion: KEMOPLAT 1 mg/ml should be added to 2 liters of 0.9% sodium chloride injection or Dextrose-Saline solution.
Treatment: Following pre-hydration, KEMOPLAT 1 mg/ml infusion is administered over 1-2 hrs. A longer infusion time of 6-8 hrs may decrease gastrointestinal and renal toxicities.
Post Treatment Hydration: It is recommended that I.V. hydration should continue after treatment with administration of 2 liters 0.9% sodium chloride I.V. infusion or Dextrose-saline over a period of 6-12 hours.
Note: Since aluminum reacts with and inactivates cisplatin, it is important not to use needles or other equipment that contain aluminum while preparing or administering KEMOPLAT 1 mg/ml.